Skip to main navigation Skip to search Skip to main content

Design and synthesis of tailored human caseinolytic protease P inhibitors

  • Thomas F. Gronauer
  • , Melanie M. Mandl
  • , Markus Lakemeyer
  • , Mathias W. Hackl
  • , Martina Meßner
  • , Vadim S. Korotkov
  • , Johanna Pachmayr
  • , Stephan A. Sieber
  • Technical University of Munich
  • University of Munich
  • University Children’s Hospital

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Human caseinolytic protease P (hClpP) is important for degradation of misfolded proteins in the mitochondrial unfolded protein response. We here introduce tailored hClpP inhibitors that utilize a steric discrimination in their core naphthofuran scaffold to selectively address the human enzyme. This novel inhibitor generation exhibited superior activity compared to previously introduced beta-lactones, optimized for bacterial ClpP. Further insights into the bioactivity and binding to cellular targets were obtained via chemical proteomics as well as proliferation- and migration studies in cancer cells.

Original languageEnglish
Pages (from-to)9833-9836
Number of pages4
JournalChemical Communications
Volume54
Issue number70
DOIs
StatePublished - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Design and synthesis of tailored human caseinolytic protease P inhibitors'. Together they form a unique fingerprint.

Cite this